Timentin

Infection
Treatment
6 Active Studies for Timentin

What is Timentin

TicarcillinThe Generic name of this drug
Treatment SummaryClavulanic acid is a medication used in combination with other antibiotics, such as amoxicillin or ticarcillin, to fight antibiotic-resistant bacteria. Clavulanic acid comes from a bacteria known as Streptomyces clavuligerus and is often referred to as Augmentin, Co-Amoxiclav, or Clavulin when combined with amoxicillin. It prevents the degradation of other antibiotics by beta-lactamase enzymes, allowing them to be effective against a wider range of bacteria.
Timentinis the brand name
image of different drug pills on a surface
Timentin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Timentin
Ticarcillin
1990
4

Effectiveness

How Timentin Affects PatientsClavulanic acid helps antibiotics like amoxicillin to work better against bacteria. It does this by making the bacteria unable to break down the antibiotics, so that the antibiotics can fight the infection.
How Timentin works in the bodyClavulanic acid blocks the action of beta-lactamases, enzymes that break down certain antibiotics. By doing this, it allows antibiotics to remain effective in treating bacterial infections.

When to interrupt dosage

The advocated measure of Timentin is contingent upon the recognized health problem, such as Upper Respiratory Tract Infection, bacteroides fragilis and Staph Aureus Infection. The quantity of dosage is dependent on the technique of delivery which can be found in the table below.
Condition
Dosage
Administration
Infection
1000.0 mg, , 3000.0 mg, 30000.0 mg, 30.0 mg/mL
, Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Warnings

Timentin has a total of six contraindications and should not be taken when experiencing the conditions in the table below.Timentin Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Timentin.
Common Timentin Drug Interactions
Drug Name
Risk Level
Description
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ticarcillin.
Chlormadinone
Minor
The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Ticarcillin.
Cloprostenol
Minor
The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ticarcillin.
Cyproterone acetate
Minor
The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Ticarcillin.
Demegestone
Minor
The therapeutic efficacy of Demegestone can be decreased when used in combination with Ticarcillin.
Timentin Toxicity & Overdose RiskClavulanic acid is generally considered safe, with an LD50 of over 2000mg/kg in adult rodents. However, in pre-weaning rats lower doses (125mg/kg) can cause gastrointestinal distress and mortality. Taking too much of this drug in combination with amoxicillin may lead to changes in fluid and electrolyte balance, gastrointestinal symptoms, crystalluria, renal failure, and seizures. Treatment should focus on relieving symptoms and maintaining proper fluid and electrolyte balance. Hemodialysis may be used to remove the drug from the bloodstream.
image of a doctor in a lab doing drug, clinical research

Timentin Novel Uses: Which Conditions Have a Clinical Trial Featuring Timentin?

49 active clinical trials are being conducted to assess the potential of Timentin in treating Lower Respiratory Tract Infection (LRTI), Pseudomonas Aeruginosa and bacteroides fragilis.
Condition
Clinical Trials
Trial Phases
Infection
6 Actively Recruiting
Not Applicable, Phase 1

Timentin Reviews: What are patients saying about Timentin?

3Patient Review
1/19/2008
Timentin for Bacterial Pneumonia caused by Staphylococcus
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about timentin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the generic name for TIMENTIN?

"This is the name of the medication. Ticarcillin/clavulanate potassium is an antibiotic used to treat infections caused by bacteria. It is given by injection into a vein."

Answered by AI

What is TIMENTIN used for?

"Timentin is a prescription medicine used to treat the symptoms of various types of bacterial infections. These include infections of the blood (septicemia), lungs (lower respiratory infections), bones and joints (bone and joint infections), urinary tract (urinary tract infections), lining of the abdomen (intra-abdominal infections), and female reproductive organs (gynecologic infections). Timentin may be used alone or in combination with other medications."

Answered by AI

Is TIMENTIN still available?

"We are alerting you that GlaxoSmithKline has stopped making TIMENTIN® for the US."

Answered by AI

What type of drug is TIMENTIN?

"TIMENTIN consists of the semisynthetic antibiotic ticarcillin disodium and the β-lactamase inhibitor clavulanate potassium. It is for intravenous administration and is sterile and injectable."

Answered by AI

Clinical Trials for Timentin

Image of National Institutes of Health Clinical Center in Bethesda, United States.

gp91 Grans for Chronic Granulomatous Disease

18 - 75
Male
Bethesda, MD
Background: CGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get frequent or life-threatening infections. Researchers want to see if a new procedure can help a person s cells kill germs for a short time. It uses messenger RNA (mRNA) to deliver correct instructions for the gene mutation to the cells. Objective: To test a procedure in which mRNA is added to a person s blood cells. Eligibility: Males aged 18-75 with CGD with a mutation in the gene that makes the protein gp91phox. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Swab to test for strep throat Some screening tests will be repeated during the study. Participants will be admitted to the NIH Clinical Center hospital for at least 7 days. They will have apheresis. For this, a medicine is injected under their skin to prepare their white blood cells for collection. An IV line is placed into an arm vein. Blood goes through the IV line into a machine that divides whole blood into red blood cells, plasma, and white blood cells. The white blood cells are removed, and the rest of the blood is returned to the participant through an IV line in their other arm. The next day, they will get their mRNA-corrected cells via IV. They will be monitored for 3 more days. After discharge, participants will keep a symptom diary. They will be contacted weekly for one month, and then once a month. They will have a follow-up visit 3 months after the infusion.
Phase 1
Recruiting
National Institutes of Health Clinical CenterSuk S De Ravin, M.D.
Image of University of Connecticut in Farmington, United States.

Prostate Biopsy Techniques for Reducing Infection Risk

18+
Male
Farmington, CT
Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora. Preliminary data demonstrates that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer. This randomized controlled trial will be the first prospective study to evaluate in-office transperineal MRI targeted prostate biopsy. The investigators hypothesize that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer.
Recruiting
Has No Placebo
University of Connecticut (+16 Sites)Jim C Hu, MD MPH
Image of University of Iowa in Iowa City, United States.

Improved Perioperative Preventive Measures for Surgical Site Infections

18+
All Sexes
Iowa City, IA
Surgical site infections (SSIs) are associated with increased patient morbidity, mortality, and healthcare costs. ESKAPE (Enterococcus, S. aureus, Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter spp.) pathogens are particularly pathogenic because they have increased capacity to acquire resistance and virulence traits. The investigators have proven that a multifaceted program involving improved basic perioperative preventive measures can generate substantial reductions in S. aureus transmission and significant reductions in SSIs (88% reduction as compared to usual care). In this study, the investigators aim to examine the relative effectiveness of each component of this program in controlling ESKAPE transmission and reducing SSIs and to identify an optimal implementation strategy for national dissemination. Randomization occurs at the site level, and sites adopt preventative programs. This work will improve perioperative patient safety for the 51 million patients who undergo surgery each year.
Recruiting
Has No Placebo
University of Iowa (+2 Sites)Jeremiah R Brown, PhD
Image of University of Ottawa Heart Institute in Ottawa, Canada.

Barrier Dressing for Infections

18+
All Sexes
Ottawa, Canada
This study will evaluate the effect of an iodine impregnated barrier dressing on device pocket swab culture positivity. Minimizing contamination during the implant procedure can be one of the potential improvements to prevent CIED infections. Patients requiring a lead change, battery change or device upgrade will be eligible. This is a randomized, blinded study where participants will be randomized to having the barrier dressing applied before any incision is made (experimental group) or applying the dressing just prior to collecting the culture swab (control group). Patients and the staff taking the culture swab at the end of the procedure are blinded as to which group the participant is randomized to.
Waitlist Available
Has No Placebo
University of Ottawa Heart InstituteAlper Aydin, Dr.
Have you considered Timentin clinical trials? We made a collection of clinical trials featuring Timentin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security